# PT-141 References: The Cited Bremelanotide Literature, With DOIs and PubMed Links

> PT-141 references: the full cited bremelanotide literature — the RECONNECT trials, the 52-week extension, the fMRI study, the FDA label, and the safety record, each with a DOI or PubMed link.

Every quantitative claim on this site traces to one of these sources. Each carries a DOI, PMID, or direct link.

## How to read this register

These are the primary sources behind every figure on this site — the pivotal RECONNECT trials, the 52-week safety-and-efficacy extension, the mechanistic fMRI study, the FDA prescribing information, the cardiovascular and program-level safety analyses, the foundational pharmacology, and recent reviews. Each entry below carries its journal citation and a DOI, PMID, or direct link so any claim can be checked at source. The unverified field-reports on the [PT-141 side effects](/side-effects) page are deliberately **not** in this register — they are attributed to no journal and cite nothing, by design.

## References

[1] Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. https://pubmed.ncbi.nlm.nih.gov/12851303/
[2] Pfaus J, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101:10201-10204. https://pubmed.ncbi.nlm.nih.gov/15226502/
[3] Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
[4] Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. https://pubmed.ncbi.nlm.nih.gov/31599847/
[5] Thurston L, Hunjan T, Mills EG, Wall MB, Ertl N, Phylactou M, Muzi B, Patel B, Alexander EC, Suladze S, Modi M, Eng PC, Bassett PA, Abbara A, Goldmeier D, Comninos AN, Dhillo WS. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. J Clin Invest. 2022;132(19):e152341. https://pubmed.ncbi.nlm.nih.gov/36189794/
[6] U.S. Food and Drug Administration / DailyMed. Bremelanotide Injection — US Prescribing Information. 2019. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9
[7] Clayton AH, Lucas J, DeRogatis LR, Jordan R. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clin Ther. 2017;39(3):514-526.e14. https://pubmed.ncbi.nlm.nih.gov/28189361/
[8] Clayton AH, Kingsberg SA, Portman D, Sadiq A, Jordan R, Lucas J, Spana C, Simon JA. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022;31(2):171-182. https://doi.org/10.1089/jwh.2021.0191
[9] Cipriani S, Maseroli E, Vignozzi L. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert Opin Pharmacother. 2023;24(1):15-21. https://pubmed.ncbi.nlm.nih.gov/36242769/
[10] National Institute of Diabetes and Digestive and Kidney Diseases (LiverTox). Bremelanotide — Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf. 2021. https://www.ncbi.nlm.nih.gov/books/NBK573221/
[11] Kim S, Cho MC, Cho SY, Chung H, Rajasekaran MR. Novel Emerging Therapies for Erectile Dysfunction. World J Mens Health. 2021;39(1):48-64. https://pubmed.ncbi.nlm.nih.gov/32202086/
[12] Borland JM, Kohut-Jackson AL, Peyla AC, Hall MA, Mermelstein PG, Meisel RL. Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology. 2025;110299. https://pubmed.ncbi.nlm.nih.gov/39793696/
[13] White WB, Myers MG, Jordan R, Lucas J. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens. 2017;35(4):761-768. https://pubmed.ncbi.nlm.nih.gov/27977473/

---

A gauge-by-gauge read-out of the published PT-141 (bremelanotide) record — each cited figure sealed under glass with its source, the lone approved indication and the nausea-led tolerability cost lit first, and the unverified field reports pinned off to one side and stamped as such; no clinic behind the panel and nothing here dosed, dispensed, or sold.